Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Mirum Pharmaceuticals Inc (Mirum Pharmaceuticals) is a biopharmaceutical company that develops therapies and medicines for rare diseases. The company offers products include maralixibat which treats alagille syndrome, progressive familial intrahepatic cholestasis and cholestatic pruritus; chenodiol for cerebrotendinous xanthomatosis and cholic acid targets bile acid synthesis disorders. Its pipeline products including volixibat which targets sclerosing cholangitis and primary biliary cholangitis; brelovitug for chronic hepatitis delta virus; and MRM-3379 which targets fragile x syndrome. The company markets its products under the LIVMARLI, CTEXLI, and CHOLBAM brand names. Mirum Pharmaceuticals is headquartered in Foster City, California, the US.
Headquarters
United States of America
Address
Suite 300, 989 E Hillsdale Blvd., Foster City, California, 94404
Website
mirumpharma.com
Telephone
1 650 6674085
No of Employees
322
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MIRM (NASD)
Revenue (2024)
$521.3M
54.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
73.4%
(2024 vs 2023)
Market Cap*
$7.8B
Net Profit Margin (2024)
XYZ
82.8%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Maralixibat: | LIVMARLI |
| Alagille Syndrome (ALGS) | CTEXLI |
| Progressive Familial Intrahepatic Cholestasis (PFIC) | CHOLBAM |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In January, the company acquired Bluejay Therapeutics, a biotechnology company. |
| 2023 | Asset Purchase | In September, the company acquired bile acid product portfolio from Travere Therapeutics. |
| 2022 | Acquisitions/Mergers/Takeovers | In May, the company acquired Satiogen Pharmaceuticals, Inc, a specialty pharma company. |
Competitor Comparison
| Key Parameters | Mirum Pharmaceuticals Inc | Novartis AG | GSK plc | Sandoz Inc | Shionogi & Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United Kingdom | United States of America | Japan |
| City | Foster City | Basel | London | Princeton | Osaka |
| State/Province | California | Basel-Stadt | England | New Jersey | Osaka |
| No. of Employees | 322 | 75,267 | 66,841 | - | 4,959 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Grey | Chairman | Executive Board | 2020 | 72 |
| Christopher Peetz | Chief Executive Officer; Director | Executive Board | 2019 | 46 |
| Eric Bjerkholt | Chief Financial Officer | Senior Management | 2023 | 65 |
| Peter Radovich | Chief Operating Officer; President | Senior Management | 2020 | 47 |
| Doug Sheehy | Chief Legal Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer